Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0599 bioavailability and pharmacokinetics study in healthy volunteers
NCT05845645Phase 1Completed
- Sponsor
- UCB
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minzasolmin (2 arms), sponsored by UCB. Primary endpoints: Maximum Plasma Concentration of UCB0599 at 96 hours, Area Under the Plasma Concentration-time Curve From Time 0 to the Last Quantifiable Concentration of UCB0599 at 96 hours and 7 more. Started May 2023; status: completed.
02
Drugs
minzasolmin
Beyond the preview
Go deeper on NCT05845645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845645.